| Q4 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-02-24 | ||||||
| REV | |||||||
| Q3 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.290 | -0.330 | -0.0400 | ||||
| REV | 39.380M | 40.994M | 1.614M |
| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
You can purchase shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) through any online brokerage.
Other companies in BioCryst Pharmaceuticals’s space includes: Twist Bioscience (NASDAQ:TWST), Zentalis Pharmaceuticals (NASDAQ:ZNTL), Karuna Therapeutics (NASDAQ:KRTX), Cerevel Therapeutics Hldg (NASDAQ:CERE) and Sage Therapeutics (NASDAQ:SAGE).
The latest price target for BioCryst Pharmaceuticals (NASDAQ: BCRX) was reported by Oppenheimer on December 10, 2021. The analyst firm set a price target for 16.00 expecting BCRX to rise to within 12 months (a possible 7.60% upside). 10 analyst firms have reported ratings in the last year.
The stock price for BioCryst Pharmaceuticals (NASDAQ: BCRX) is $14.87 last updated Fri Jan 28 2022 21:00:02 GMT+0000 (Coordinated Universal Time).
There are no upcoming dividends for BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals’s $Q4 earnings are confirmed for after-market on February 24, 2022.
There is no upcoming split for BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.